Pharmaceuticals
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim d...
2026-08-31 08:00
1829
LifeTech Scientific Corporation Announces 2026 Interim Results
HONG KONG, Aug. 28, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral ...
2026-08-29 00:23
5082
Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development. P...
2026-08-28 22:30
2943
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to E...
2026-08-28 20:03
1766
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
* Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities * The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigati...
2026-08-28 20:00
1435
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating...
2026-08-28 19:31
2356
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selectiv...
2026-08-28 19:00
2023
Tigermed Announces 2026 Interim Results
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting Period"). ...
2026-08-28 17:56
3207
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2...
2026-08-28 10:44
5137
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 27, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geogr...
2026-08-28 06:58
3079
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-27 22:15
5757
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced ...
2026-08-27 22:09
2357
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today an...
2026-08-27 22:04
4960
Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform
Certification strengthens the governance framework behind NEOVAULT® as Neopharma expands from Fit-for-Duty into broader human health diagnostics NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma") today announced that it has achieved ISO/IEC 42001:2023 certification ...
2026-08-27 20:20
1570
Nature Biotechnology | Aureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental Result
SHANGHAI and LAGUNA HILLS, Calif., Aug. 26, 2026 /PRNewswire/ -- The complete
results of AIntibody, the first international AI antibody design competition,
have now been formally published inNature Biotechnology.
2026-08-27 08:00
2528
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings G...
2026-08-26 22:57
4660
Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey MUMBAI, India, Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released itsSustainability Re...
2026-08-26 22:49
4856
ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements BRISBANE, Calif., Aug. 26, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company adv...
2026-08-26 21:00
2713
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietar...
2026-08-26 20:02
1694
SU Group Wins US$2.4 Million Follow-on Award, Expanding Landmark Smart-Hospital Project to US$13.7 Million
Additional Award Broadens the Company's Role in Mission-Critical Healthcare Infrastructure and Strengthens Revenue Visibility HONG KONG, Aug. 26, 2026 /PRNewswire/ -- SU Group Holdings Limited (Nasdaq: SUGP) ("SU Group" or the "Company"), an integrated security-related engineering services compa...
2026-08-26 20:00
3029
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
8089
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
8074
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
7860
